Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Investigating the recent interim data from the phase 2 CALLIPER trial of vidofludimus calcium (IMU-838) in patients with progressive multiple sclerosis.

Ticker(s): IMUX

Who's the expert?

Institution: Swedish Health Services

Medical Director for Neurology Research and practicing Neurologist at the Swedish Neuroscience Institute.
Specializes in the treatment of Multiple Sclerosis and prescribes Ocrevus and Dimethyl fumarate most commonly to his 800 MS patients.
His research in multiple sclerosis and neurochemistry has been recognized in numerous peer-reviewed scientific journals including the Journal of Neuroscience and the Journal of Neurochemistry.

Interview Goal

This call will include a discussion on the current standard of care and the potential of vidofludimus calcium (IMU-838), a nuclear receptor related 1 (Nurr1) activator being developed by Immunic Therapeutics for the treatment of progressive multiple sclerosis including the the recent interim data from the phase 2 CALLIPER trial.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.